Aug 15, 2018
Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference
Aug 07, 2018
TACTI-mel Patient Recruitment Complete and Operational Update
Jul 30, 2018
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
Jul 02, 2018
Immutep Submits Investigational New Drug (IND) Application with FDA
May 29, 2018
Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast
May 16, 2018
Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
May 04, 2018
Immutep to Present at 2018 ASCO Annual Meeting
Apr 12, 2018
Immutep Completes $6.31 Million Share Purchase Plan; Raises Total of $13.16 Million
Apr 02, 2018
Operational Update
Mar 21, 2018
Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
Immutep Commences Patient Dosing In Additional TACTI-mel Cohort
Mar 11, 2018
Immutep Raises A$6.85M Through Institutional Placement
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD
Mar 05, 2018
Immutep Announces United States Patent Grant for IMP701 Antibody
Mar 04, 2018
Immutep receives A$686,704 R&D Tax Incentive
